Home > Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl.

Chambers, Laura C and Hallowell, Benjamin D and Zullo, Andrew R and Paiva, Taylor J and Berk, Justin and Gaither, Rachel and Hampson, Aidan J and Beaudoin, Francesca L and Wightman, Rachel S (2023) Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. JAMA Network Open, 6, (9), e2334540. doi: 10.1001/jamanetworkopen.2023.34540.

External website: https://jamanetwork.com/journals/jamanetworkopen/f...

Importance: Buprenorphine treatment for opioid use disorder (OUD) has more than doubled since 2009. However, current US Food and Drug Administration buprenorphine dosing guidelines are based on studies among people using heroin, prior to the emergence of fentanyl in the illicit drug supply.

Question: Are higher doses of buprenorphine treatment for opioid use disorder associated with improved retention in treatment when use of fentanyl (vs heroin) is more prevalent?

Findings: In this cohort study of 6499 patients initiating buprenorphine treatment between 2016 and 2020, those prescribed the recommended daily dose (16 mg) were at significantly greater risk of treatment discontinuation within 180 days than those prescribed a higher dose (24 mg).

Meaning: The results of this study suggest that the value of higher buprenorphine doses than currently recommended needs to be considered for improving retention in treatment.


Repository Staff Only: item control page